Coadministration is contraindicated. Co-administration may significantly decrease rilpivirine plasma concentration. This may result in loss of therapeutic effect of Juluca. Coadministration with dolutegravir has not been studied but no effect on dolutegravir pharmacokinetics is expected. Coadministration with rilpivirine has not been studied but significant decreases in rilpivirine plasma concentrations are expected (reduced absorption due to gastric pH increase).

Coadministration is contraindicated due to potential for significant decreases in rilpivirine plasma concentrations due to gastric pH increase, which may result in loss of virologic response.